| Type | Title | Date Released | |
|---|---|---|---|
8-K | Keros Therapeutics Highlights Rinvatercept (KER-065) Clinical Progress for Neuromuscular Diseases in November 2026 Corporate Presentation | ||
10-Q | Form 10-Q | ||
8-K | Keros Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights | ||
SCHEDULE 13G/A | BlackRock Portfolio Management LLC (Filed by) | ||
8-K | Keros Therapeutics to Receive $20 Million Development Milestone Payment from Partner Takeda | ||
8-K | Keros Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Rinvatercept for Duchenne Muscular Dystrophy | ||
EFFECT | Form EFFECT | ||
DEL AM | Form DEL AM | ||
S-3 | September 2026 SHELF + ATM | ||
8-K | Keros Therapeutics Announces $5 Million Share Repurchase Authorization | ||
4 | Tanini Annita (Reporting) | ||
4 | Lerner Lorena Raquel (Reporting) |
